Form 13-F position report

EDGEWISE THERAPEUTICS INC

Reported by VIKING GLOBAL INVESTORS LP

EWTX CUSIP 28036F105 Manager CIK 0001103804

Reported 0 shares, down 490,035 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2025
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 18 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 41672000
2022-03-31 26454000
2022-06-30 21709000
2022-09-30 43386000
2022-12-31 39417765
2023-03-31 32744004
2023-06-30 46060273
2023-09-30 35291907
2023-12-31 67381057
2024-03-31 60906023
2024-06-30 26675439
2024-09-30 39531787
2024-12-31 32707126
2025-03-31 10780770
2025-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

15 quarters
Quarterly reported position history for EDGEWISE THERAPEUTICS INC held by VIKING GLOBAL INVESTORS LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2025 Reduced 0 -490,035 (-100.0%) 0 $0 2025-08-14
Q1 2025 Reduced 490,035 -734,951 (-60.0%) 0.03% $10,780,770 2025-05-15
Q4 2024 Reduced 1,224,986 -256,160 (-17.3%) 0.11% $32,707,126 2025-02-14
Q3 2024 Unchanged 1,481,146 0 (0.0%) 0.14% $39,531,787 2024-11-14
Q2 2024 Reduced 1,481,146 -1,858,000 (-55.6%) 0.1% $26,675,439 2024-08-14
Q1 2024 Reduced 3,339,146 -2,820,000 (-45.8%) 0.23% $60,906,023 2024-05-15
Q4 2023 Unchanged 6,159,146 0 (0.0%) 0.25% $67,381,057 2024-02-14
Q3 2023 Added 6,159,146 +215,885 (3.6%) 0.14% $35,291,907 2023-11-14
Q2 2023 Added 5,943,261 +1,034,115 (21.1%) 0.19% $46,060,273 2023-08-14
Q1 2023 Added 4,909,146 +500,000 (11.3%) 0.15% $32,744,004 2023-05-15
Q4 2022 Unchanged 4,409,146 0 (0.0%) 0.2% $39,417,765 2023-02-14
Q3 2022 Added 4,409,146 +1,681,897 (61.7%) 0.2% $43,386,000 2022-11-14
Q2 2022 Unchanged 2,727,249 0 (0.0%) 0.1% $21,709,000 2022-08-15
Q1 2022 Unchanged 2,727,249 0 (0.0%) 0.11% $26,454,000 2022-05-16
Q4 2021 Unchanged 2,727,249 0 (0.0%) 0.12% $41,672,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

222 managers reported EDGEWISE THERAPEUTICS INC for Q2 2025.

Managers reporting EDGEWISE THERAPEUTICS INC in Q2 2025.
Manager Activity Shares Change % of reported 13F Reported value Tenure
ORBIMED ADVISORS LLC Added 15,518,492 +496,771 5.1% $203,447,430 18 qtrs
RA CAPITAL MANAGEMENT L P Added 9,902,633 +993,542 2.19% $129,823,519 6 qtrs
BAKER BROS ADVISORS LP Added 7,305,940 +1,150,000 0.93% $95,780,873 18 qtrs
BlackRock Inc Added 6,781,046 +296,038 < 0.01% $88,899,513 4 qtrs
Paradigm Biocapital Advisors LP Added 6,142,344 +1,747,788 3.44% $80,526,130 6 qtrs
JANUS HENDERSON GROUP PLC Added 5,503,349 +221,195 0.04% $72,134,463 18 qtrs
Novo Holdings A S Unchanged 5,350,000 0 4.95% $70,138,500 18 qtrs
BRAIDWELL LP Added 5,210,831 +2,752,023 2.34% $68,313,994 4 qtrs
VANGUARD GROUP INC Added 4,841,500 +547,096 < 0.01% $63,472,065 18 qtrs
PERCEPTIVE ADVISORS LLC Reduced 4,639,949 -1,907,379 2.26% $60,829,731 7 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 14, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.